Study #2023-0775
A phase II study of reduced dose post transplantation cyclophosphamide as GVHD prophylaxis in adult patients with hematologic malignancies receiving HLA-mismatched unrelated donor peripheral blood stem cell transplantation
MD Anderson Study Status
Enrolling
Treatment Agent
Busulfan, Fludarabine, Post-Transplant Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Melphalan, Mesna, Cyclophosphamide
Description
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question\[s\] it aims to answer are: * Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant? * Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard dose of PTCy?
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasm, Lymphoma, Chronic Myelomonocytic Leukemia, Pro-Lymphocytic Leukemia, Myelofibrosis
Study phase:
Phase II
Physician name:
Betul Oran
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-877-934-6089
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.